Business Description
Tibet Aim Pharm Inc
ISIN : CNE100002C39
Share Class Description:
SZSE:002826: ACompare
Compare
Traded in other countries / regions
002826.China IPO Date
2016-12-09Description
Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 46.85 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.19 | |||||
| Interest Coverage | 156.82 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 8.49 | |||||
| Beneish M-Score | -4.05 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.6 | |||||
| 3-Year EBITDA Growth Rate | 8.3 | |||||
| 3-Year EPS without NRI Growth Rate | 5.3 | |||||
| 3-Year Book Growth Rate | 5 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.15 | |||||
| 9-Day RSI | 39.31 | |||||
| 14-Day RSI | 45.9 | |||||
| 6-1 Month Momentum % | 39.87 | |||||
| 12-1 Month Momentum % | -5.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.51 | |||||
| Quick Ratio | 2.32 | |||||
| Cash Ratio | 1.86 | |||||
| Days Inventory | 75.84 | |||||
| Days Sales Outstanding | 45.88 | |||||
| Days Payable | 213.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.26 | |||||
| Dividend Payout Ratio | 0.13 | |||||
| 3-Year Dividend Growth Rate | 49.4 | |||||
| Forward Dividend Yield % | 0.26 | |||||
| 5-Year Yield-on-Cost % | 0.46 | |||||
| 3-Year Average Share Buyback Ratio | 0.4 | |||||
| Shareholder Yield % | 1.47 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 65.85 | |||||
| Operating Margin % | 9 | |||||
| Net Margin % | 5.19 | |||||
| FCF Margin % | 29.79 | |||||
| ROE % | 4.49 | |||||
| ROA % | 3.52 | |||||
| ROIC % | 9.73 | |||||
| ROC (Joel Greenblatt) % | 12.84 | |||||
| ROCE % | 5.93 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 66.35 | |||||
| PE Ratio without NRI | 48.41 | |||||
| Shiller PE Ratio | 37.6 | |||||
| Price-to-Owner-Earnings | 331.79 | |||||
| PEG Ratio | 7.81 | |||||
| PS Ratio | 3.42 | |||||
| PB Ratio | 2.94 | |||||
| Price-to-Tangible-Book | 3.1 | |||||
| Price-to-Free-Cash-Flow | 11.89 | |||||
| Price-to-Operating-Cash-Flow | 11.19 | |||||
| EV-to-EBIT | 40.05 | |||||
| EV-to-EBITDA | 40.05 | |||||
| EV-to-Revenue | 2.79 | |||||
| EV-to-FCF | 10.69 | |||||
| Price-to-Projected-FCF | 1.85 | |||||
| Price-to-Graham-Number | 2.58 | |||||
| Price-to-Net-Current-Asset-Value | 7.09 | |||||
| Price-to-Net-Cash | 12.82 | |||||
| Earnings Yield (Greenblatt) % | 2.5 | |||||
| FCF Yield % | 8.89 | |||||
| Forward Rate of Return (Yacktman) % | 3.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tibet Aim Pharm Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 641.581 | ||
| EPS (TTM) (Â¥) | 0.17 | ||
| Beta | 0.7 | ||
| Volatility % | 40.51 | ||
| 14-Day RSI | 45.9 | ||
| 14-Day ATR (Â¥) | 0.663617 | ||
| 20-Day SMA (Â¥) | 12.181 | ||
| 12-1 Month Momentum % | -5.39 | ||
| 52-Week Range (Â¥) | 5.57 - 13.62 | ||
| Shares Outstanding (Mil) | 190.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tibet Aim Pharm Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tibet Aim Pharm Inc Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tibet Aim Pharm Inc Frequently Asked Questions
What is Tibet Aim Pharm Inc(SZSE:002826)'s stock price today?
The current price of SZSE:002826 is ¥11.28. The 52 week high of SZSE:002826 is ¥13.62 and 52 week low is ¥5.57.
When is next earnings date of Tibet Aim Pharm Inc(SZSE:002826)?
The next earnings date of Tibet Aim Pharm Inc(SZSE:002826) is .
Does Tibet Aim Pharm Inc(SZSE:002826) pay dividends? If so, how much?
The Dividend Yield %  of Tibet Aim Pharm Inc(SZSE:002826) is 0.26% (As of Today), Highest Dividend Payout Ratio of Tibet Aim Pharm Inc(SZSE:002826) was 0.67. The lowest was 0.13. And the median was 0.32. The  Forward Dividend Yield % of Tibet Aim Pharm Inc(SZSE:002826) is 0.26%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers